Your browser doesn't support javascript.
loading
Percutaneous ablative therapies for hepatocellular carcinoma in the caudate lobe of the liver: efficacy and outcome.
Mukund, Amar; Tripathy, Tara Prasad; Patel, Ranjan Kumar; Chandel, Karamvir; Patidar, Yashwant; Jindal, Ankur; Sarin, Shiv Kumar.
Afiliação
  • Mukund A; Department of Interventional Radiology, Institute of Liver & Biliary Sciences, New Delhi, India.
  • Tripathy TP; Department of Radiology, AIIMS, Bhubaneswar, India.
  • Patel RK; Department of Radiology, AIIMS, Bhubaneswar, India.
  • Chandel K; Department of Interventional Radiology, Institute of Liver & Biliary Sciences, New Delhi, India.
  • Patidar Y; Department of Interventional Radiology, Institute of Liver & Biliary Sciences, New Delhi, India.
  • Jindal A; Department of Hepatology, Institute of Liver & Biliary Sciences, New Delhi, India.
  • Sarin SK; Department of Hepatology, Institute of Liver & Biliary Sciences, New Delhi, India.
Br J Radiol ; 96(1148): 20220086, 2023 Aug.
Article em En | MEDLINE | ID: mdl-37227887
ABSTRACT

OBJECTIVE:

To assess the efficacy and outcomes of percutaneous ablative therapies for hepatocellular carcinoma (HCC) in the caudate lobe.

METHODS:

Patients within Milan criteria, who underwent thermal ablation (RFA/MWA) for HCC were analyzed. Based on the inclusion-criteria, patients were categorized in two groups. Group-1 (caudate-lobe HCC) and Group-2 (non-caudate-lobe HCC). Both the groups were analyzed for technical success (TS), local tumor progression (LTP), disease-free survival (DFS), and overall survival (OS) were compared between both the groups. Predictive factors for LTP, DFS, or OS in the study cohort were analyzed using appropriate statistical analyses.

RESULTS:

Twenty-one patients qualified to be in Group-1 while 130 patients fulfilled the criteria for Group-2. TS of 90.5 and 97.7% was seen after the first session of ablation for Group-1 and group-2 respectively, while a TS of 95.2% (Group-1) and 100% (Group-2) was achieved after second session. The right-intercostal-approach was used in 66.7% (n = 14) and the anterior-epigastric-approach was used in 33.3% (n = 7) of patients having caudate-lobe HCC. Procedure-related complications in both the groups were comparable. Although, statistically insignificant, LTP in the Group-1 (19.5%, n = 4) was twice that of non-caudate lobe HCC (8.5%, n = 11). The cumulative DFS rate was better in Group-2 while OS in both groups were comparable. Multivariate analysis showed tumor size and ablative margin of 5 mm being independent predictors of LTP after percutaneous-ablation of caudate-lobe HCC.

CONCLUSION:

Ablative therapies for HCC in caudate lobe is feasible and safe with comparable LTP and OS to non-caudate lobe HCC. Tumor size >2 cm and lack of 5 mm ablative margin are independent predictors of LTP. ADVANCES IN KNOWLEDGE 1. Percutaneous ablation of caudate lobe HCC is feasible using anterior epigastric approach or right intercostal approach. 2. These approaches may allow a safe and effective ablation of caudate lobe HCC with results comparable to non-caudate HCC ablation.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ablação por Cateter / Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ablação por Cateter / Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article